Skip to main content
Fig. 6 | Stem Cell Research & Therapy

Fig. 6

From: Inhibitory effects of metformin at low concentration on epithelial–mesenchymal transition of CD44+CD117+ ovarian cancer stem cells

Fig. 6

Metformin and cisplatin inhibit tumor growth in patient-derived xenograft mice. Six to 8 weeks after subcutaneous injection of ovarian patient ovarian cancer cells, the treatments were started when the tumor size reached approximately 150 mm3. Four groups of mice (n = 6) were treated with saline, metformin, cisplatin, and the combination of metformin and cisplatin for 4 weeks. Tumor size and body weight were measured weekly throughout the experiment period. Three mice from each group were sacrificed after 4 weeks of treatment for analysis and the other three mice were kept to observe for an additional 5 weeks. Summary results from three separate experiments are presented (a). Flow cytometry was performed to isolate CD44+CD117+ CSCs of each treatment group. Metformin treatment significantly reduced the CD44+CD117+ CSC population (b). Metformin significantly reduced snail2, twist, and vimentin, but not Snail1expression, and upregulated E-cadherin expression (c). * Significant difference compared with control (P < 0.05)

Back to article page